Key facts
- Huixin Lifetech’s last known valuation is $135.9M (Jan 2026).
- It has raised $29.5M; the latest was Later Stage VC ($14.2M) in Jan 2026.
- Notable investors include Legend Capital, Co-Win Ventures, South China Venture Capital, Green River Investment, HaoYue Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Huixin Lifetech
- ·The full record, as it builds
Funding rounds
No funding rounds for Huixin Lifetech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huixin Lifetech
Developer of technology and diagnostic products in the field of liquid biopsy. The company offers research and development and application of exosomes in early diagnosis and treatment of diseases, especially combining exosomes with liquid biopsy techniques including various medical equipment, general laboratory reagents, and microfluidic chip, thereby enabling patients with solutions that could achieve early screening of cancer.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2017
- Website
- huixinbio.com/
- Ownership
- Privately Held (backing)
Huixin Lifetech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huixin Lifetech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huixin Lifetech in its N-PORT filings yet. We sweep new filings monthly.